Arrowhead to Webcast Fiscal 2016 First Quarter Results
February 02 2016 - 4:01PM
Business Wire
Arrowhead Research Corporation (NASDAQ: ARWR), a
biopharmaceutical company developing targeted RNAi therapeutics,
today announced that it will host a webcast and conference call on
Tuesday, February 9, 2015, at 4:30 p.m. EST to discuss its
financial results for the fiscal 2016 first quarter ended December
31, 2015. Investors may access a live audio webcast on the
Company's website at http://ir.arrowheadresearch.com/events.cfm.
For analysts that wish to participate in the conference call,
please dial 855-215-6159 or 315-625-6887 and enter Conference ID
40876476.
A replay of the webcast will be available on the company’s
website approximately two hours after the conclusion of the call
and will remain available for 90 days. An audio replay will also be
available approximately two hours after the conclusion of the call
and will be available for 3 days. To access the audio replay, dial
855-859-2056 or 404-537-3406 and enter Conference ID 40876476.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company
developing targeted RNAi therapeutics. The company is leveraging
its proprietary Dynamic Polyconjugate™ delivery platform to develop
targeted drugs based on the RNA interference mechanism that
efficiently silences disease-causing genes. Arrowhead’s pipeline
includes ARC-520 and ARC-521 for chronic hepatitis B virus, ARC-AAT
for liver disease associated with alpha-1 antitrypsin deficiency,
ARC-F12 for hereditary angioedema and thromboembolic diseases, and
ARC-HIF2 for renal cell carcinoma.
For more information please visit
http://www.arrowheadresearch.com, or follow us on Twitter
@ArrowRes. To be added to the Company's email list and receive news
directly, please visit
http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our
ability to successfully develop drug candidates, the timing for
starting and completing clinical trials, the timing of any market
authorization, the timing of any market authorization for
competitive products, rapid technological change in our markets,
and the enforcement of our intellectual property rights. Arrowhead
Research Corporation's most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q discuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to
update or revise forward-looking statements to reflect new events
or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead
Research Corporation.
Source: Arrowhead Research Corporation
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160202005309/en/
Arrowhead Research CorporationVince Anzalone,
CFA626-304-3400ir@arrowres.comorInvestor Relations:The Trout
GroupChad Rubin, 646-378-2947ir@arrowres.comorMedia:Russo
PartnersMatt Middleman,
M.D.212-845-4272matt.middleman@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024